Harmony biosciences receives u.s. food and drug administration approval for wakix® (pitolisant) in pediatric patients with narcolepsy

Plymouth meeting, pa. , june 24, 2024 /prnewswire/ -- harmony biosciences (nasdaq: hrmy) today announced that the u.s. food and drug administration (fda) has approved its supplemental new drug application (snda) for wakix® (pitolisant) tablets for the treatment of excessive daytime sleepiness (eds) in pediatric patients 6 years of age and older with narcolepsy.
DRUG Ratings Summary
DRUG Quant Ranking